Expanding anti-CD38 immunotherapy for lymphoid malignancies.
Xu WangXinfang YuWei LiPraveen NeeliMing LiuLing LiMingzhi ZhangXiaosheng FangKen H YoungYong LiPublished in: Journal of experimental & clinical cancer research : CR (2022)
These findings may expand anti-CD38 immunotherapy to a broad spectrum of lymphoid malignancies and call for the incorporation of ATRA into daratumumab or other anti-CD38 immunological agents for cancer therapy.
Keyphrases